Plain-English translation of NCT06686979 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Salivary gland cancer that has come back or spread is difficult to treat because every patient's cancer behaves differently. This study is testing whether doctors can grow a small sample of your cancer cells in the lab—in a special 3D structure called an organoid—and then test different drugs against those cells to figure out which drug will work best for you personally.
Right now, doctors have to guess which drug will work for your cancer based on general guidelines and experience. This new approach could let them test your actual cancer cells against available drugs before you start treatment, potentially saving you time and side effects by avoiding drugs that won't help.
You likely qualify if…
You likely don't qualify if…
You will undergo standard cancer treatment chosen by your doctor based on current guidelines. At the same time, researchers will take a sample of your cancer tissue and grow it in the lab to test how it responds to different drugs. The study will track how well your actual treatment works and compare those results to what the lab tests predicted, helping doctors understand if this new testing method could improve treatment choices for future patients.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China
Sponsor
Huashan Hospital
Collaborators
Shanghai Cancer Hospital, China, Eye & ENT Hospital of Fudan University
Enrollment target
~40 participants
Started
March 2025
Primary completion
November 2026
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lai-ping Zhong, MD, PhD
Huashan Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.